Ventiv Health acquires InChord in $185 million deal

Share this article:
Contract sales firm Ventiv Health has agreed to buy independent healthcare marketing and advertising network InChord for $185 million in cash and stock.
InChord chairman and chief executive Blane Walter, who will preside over Ventiv's communications division, said the deal offers a good cultural and strategic fit for both companies. "There are no redundancies between our capabilities and those of Ventiv," said Walter. "We serve the same industry, and there's little overlap in our clients."
As a result, InChord will continue to operate from its current offices and under its current brands, Walter said, with no layoffs. The InChord chief talked to several big marketing holding companies, he said, in looking for a partner, but settled on Ventiv due to its size and the potential synergy between the two firms' offerings. In particular, the two firms will be looking at pairing InChord's multi-channel marketing capabilities with Ventiv's sales analytics business.
InChord, which is headquartered in Westerville, Ohio and includes such brands as GSW Worldwide, Palio Communications and Cadent Medical Communications, is expected to contribute around 25 percent of Somerset, N.J.-based Ventiv's revenues.
Ventiv brands include Promotech and The Franklin Group. The firm, which went public in 1999, has been rapaciously acquisitive over the past year as it has extended its offering from contract sales into analytics, consulting and measurement.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.